On January 24, 2022, Hemanext announced that its innovative blood processing and storage system has been recognized by the Association for the Advancement of Blood & Biotherapies (“AABB”), a leading international association in transfusion medicine and biotherapies, for compliance with its industry-recognized quality and safety standards SCoPE Program. The Hemanext technology is the first system providing both blood processing and storage to receive this designation.
Recent Posts
- Hemanext Announces Close of Series B-2 Equity Funding Round
- Hemanext Inc. Announces First Patients Treated In A Clinical Trial Investigating the Efficacy of the Hemanext ONE® Red Blood Cell Processing and Storage System
- Hemanext signs agreement with Hemara Bio, a healthcare distributor in the U.A.E., to provide hospitals and clinicians across the GCC Region with Hemanext ONE® system
- Hemanext Inc. Announces New HCPCS Code for “Red Blood Cells, Leukocytes Reduced, Oxygen/Carbon Dioxide Reduced, Each Unit.”
- Hemanext Inc. Announces Completion of Post-Market Cancer and Burn Safety Study